COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Profitability Analysis including gross margin, operating margin, net margin, return on assets, return on equity, return on invested capital. Compare profitability against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Profitability Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.

Return on Equity (ROE)

7.63%

Increased from previous period

ROE above 1.5x 3088.T's 1.74%. David Dodd would confirm if such superior profitability is sustainable.

Return on Assets (ROA)

2.92%

Increased from previous period

ROA above 1.5x 3088.T's 0.92%. David Dodd would verify if the company’s niche or scale drives superior asset efficiency.

Return on Capital Employed (ROCE)

11.33%

Increased from previous period

ROCE 1.25-1.5x 3088.T's 9.50%. Bruce Berkowitz would confirm if the firm’s capital structure drives superior returns.

Gross Profit Margin

19.09%

Increased from previous period

Gross margin 50-75% of 3088.T's 27.83%. Martin Whitman would worry about a persistent competitive disadvantage.

Operating Profit Margin

5.97%

Increased from previous period

Operating margin below 50% of 3088.T's 12.20%. Michael Burry would investigate whether this signals deeper issues.

Net Profit Margin

3.61%

Increased from previous period

Net margin above 1.5x 3088.T's 1.79%. David Dodd would investigate if product mix or brand premium drives better bottom line.

Select Chart Metric:

3349.T Profitability Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Return on Equity (ROE)

7.63%

Increased from previous period

ROE above 1.5x 3088.T's 1.74%. David Dodd would confirm if such superior profitability is sustainable.

Return on Assets (ROA)

2.92%

Increased from previous period

ROA above 1.5x 3088.T's 0.92%. David Dodd would verify if the company’s niche or scale drives superior asset efficiency.

Return on Capital Employed (ROCE)

11.33%

Increased from previous period

ROCE 1.25-1.5x 3088.T's 9.50%. Bruce Berkowitz would confirm if the firm’s capital structure drives superior returns.

Gross Profit Margin

19.09%

Increased from previous period

Gross margin 50-75% of 3088.T's 27.83%. Martin Whitman would worry about a persistent competitive disadvantage.

Operating Profit Margin

5.97%

Increased from previous period

Operating margin below 50% of 3088.T's 12.20%. Michael Burry would investigate whether this signals deeper issues.

Net Profit Margin

3.61%

Increased from previous period

Net margin above 1.5x 3088.T's 1.79%. David Dodd would investigate if product mix or brand premium drives better bottom line.

Select Chart Metric: